XyloCor Therapeutics
Ronald Crystal, MD, is Bruce Webster Professor and Chairman, Department of Genetic Medicine, Weill Cornell Medical College and Director of the Belfer Gene Therapy Core Facility. He has been a leader in gene therapy for more than 20 years and developed the FDA-approved therapy for alpha-1 antitrypsin deficiency. Dr. Crystal is also the first to use a recombinant virus as a vehicle for in vivo gene therapy.
This person is not in the org chart
This person is not in any offices
XyloCor Therapeutics
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.